HK1164154A1 - Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide cd38 - Google Patents

Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide cd38

Info

Publication number
HK1164154A1
HK1164154A1 HK12105113.7A HK12105113A HK1164154A1 HK 1164154 A1 HK1164154 A1 HK 1164154A1 HK 12105113 A HK12105113 A HK 12105113A HK 1164154 A1 HK1164154 A1 HK 1164154A1
Authority
HK
Hong Kong
Prior art keywords
cylophosphamide
containing antibodies
antibodies recognizing
combinations containing
recognizing specifically
Prior art date
Application number
HK12105113.7A
Other languages
Chinese (zh)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1164154A1 publication Critical patent/HK1164154A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
HK12105113.7A 2008-11-28 2012-05-24 Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide cd38 HK1164154A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08291119A EP2191843A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
PCT/IB2009/055392 WO2010061360A1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide

Publications (1)

Publication Number Publication Date
HK1164154A1 true HK1164154A1 (en) 2012-09-21

Family

ID=40637068

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12105113.7A HK1164154A1 (en) 2008-11-28 2012-05-24 Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide cd38

Country Status (30)

Country Link
US (2) US20110305690A1 (en)
EP (2) EP2191843A1 (en)
JP (3) JP2012510464A (en)
KR (1) KR101749770B1 (en)
CN (1) CN102264387B (en)
AR (1) AR074221A1 (en)
AU (1) AU2009321252B2 (en)
BR (1) BRPI0922305B1 (en)
CA (1) CA2745012C (en)
CL (1) CL2011001256A1 (en)
CO (1) CO6361947A2 (en)
CR (1) CR20110283A (en)
EA (2) EA026008B1 (en)
EC (1) ECSP11011077A (en)
HK (1) HK1164154A1 (en)
HN (1) HN2011001426A (en)
MA (1) MA32894B1 (en)
ME (1) ME01139B (en)
MX (1) MX340062B (en)
MY (1) MY166530A (en)
NI (1) NI201100104A (en)
NZ (1) NZ593147A (en)
PA (1) PA8850201A1 (en)
PE (1) PE20110822A1 (en)
SV (1) SV2011003925A (en)
TW (1) TWI457346B (en)
UA (1) UA104161C2 (en)
UY (1) UY32267A (en)
WO (1) WO2010061360A1 (en)
ZA (1) ZA201103920B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
MX350540B (en) 2010-09-27 2017-09-08 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl.
UA112170C2 (en) 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB
JOP20210044A1 (en) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
EP2900232B1 (en) 2012-09-25 2017-11-15 MorphoSys AG Combinations and uses thereof
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (en) * 2012-12-07 2018-12-26 Санофі Compositions comprising anti-cd38 antibodies and lenalidomide
EP3805266A1 (en) * 2013-10-31 2021-04-14 Sanofi Specific anti-cd38 antibodies for treating human cancers
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2016022589A2 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
AU2015315396B2 (en) 2014-09-09 2020-10-08 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
PE20171094A1 (en) 2014-12-04 2017-08-07 Janssen Biotech Inc ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
UA124143C2 (en) 2015-05-20 2021-07-28 Янссен Байотек, Інк. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
CA2990406A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SI3370770T1 (en) 2015-11-03 2021-03-31 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
WO2019089832A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2020187718A1 (en) 2019-03-15 2020-09-24 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
US20210188996A1 (en) 2019-12-05 2021-06-24 Sanofi-Aventis U.S. Llc Formulations of anti-cd38 antibodies for subcutaneous administration
AU2022208200A1 (en) 2021-01-14 2023-07-20 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (en) 2021-03-01 2023-01-16 德商莫菲西斯公司 Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
TW202321303A (en) 2021-07-19 2023-06-01 德商莫菲西斯公司 Treatment of anti-pla2r-autoantibody-mediated membranous nephropathy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (en) 1991-05-17 2006-01-12 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP4312259B2 (en) 1995-04-27 2009-08-12 アムジェン フレモント インク． Human antibodies derived from immunized XenoMouse
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR100643058B1 (en) 1996-12-03 2006-11-13 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
DK0970126T3 (en) 1997-04-14 2001-08-13 Micromet Ag Hitherto unknown method for the preparation of anti-human antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2329940A1 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
GB0221574D0 (en) * 2002-09-17 2002-10-23 Isis Innovation Treatments
EA037929B1 (en) * 2005-03-23 2021-06-08 Генмаб А/С Antibodies against human cd38 and use thereof
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2009094391A1 (en) * 2008-01-23 2009-07-30 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
UA112170C2 (en) * 2010-12-10 2016-08-10 Санофі ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB

Also Published As

Publication number Publication date
PE20110822A1 (en) 2011-11-22
CN102264387A (en) 2011-11-30
EA201692041A1 (en) 2017-05-31
NI201100104A (en) 2011-09-26
JP2012510464A (en) 2012-05-10
MY166530A (en) 2018-07-10
MX2011005538A (en) 2011-10-10
CA2745012A1 (en) 2010-06-03
EA201100869A1 (en) 2011-10-31
EP2370097A1 (en) 2011-10-05
CA2745012C (en) 2020-09-15
UY32267A (en) 2010-06-30
CR20110283A (en) 2011-09-20
JP2015120729A (en) 2015-07-02
MX340062B (en) 2016-06-23
US20170056496A1 (en) 2017-03-02
PA8850201A1 (en) 2010-07-27
BRPI0922305A2 (en) 2016-06-21
JP2017036297A (en) 2017-02-16
WO2010061360A1 (en) 2010-06-03
HN2011001426A (en) 2014-01-13
TWI457346B (en) 2014-10-21
EA026008B1 (en) 2017-02-28
AU2009321252B2 (en) 2016-06-09
ME01139B (en) 2013-03-20
EA032934B1 (en) 2019-08-30
KR20110096552A (en) 2011-08-30
TW201024315A (en) 2010-07-01
BRPI0922305B1 (en) 2022-04-05
JP6018235B2 (en) 2016-11-02
CO6361947A2 (en) 2012-01-20
EP2370097B1 (en) 2019-01-09
JP6215429B2 (en) 2017-10-18
KR101749770B1 (en) 2017-06-22
US20110305690A1 (en) 2011-12-15
CL2011001256A1 (en) 2012-01-27
EP2191843A1 (en) 2010-06-02
AU2009321252A1 (en) 2010-06-03
AR074221A1 (en) 2010-12-29
ECSP11011077A (en) 2011-07-29
SV2011003925A (en) 2011-10-07
UA104161C2 (en) 2014-01-10
ZA201103920B (en) 2012-09-26
NZ593147A (en) 2012-12-21
MA32894B1 (en) 2011-12-01
CN102264387B (en) 2015-04-08

Similar Documents

Publication Publication Date Title
HK1164154A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide cd38
HRP20181787T1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
HK1164165A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan cd38
ZA201104064B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
HK1164153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine cd38
RS59769B1 (en) Antibodies against human cd38
GB2468261B (en) Enhanced note processing
IL218108A (en) Anti-il1rap antibody for use in treating leukemia
EP2408814A4 (en) Carrier immunoglobulins and uses thereof
HRP20150133T1 (en) Cereal-based instant drink
EP2331134A4 (en) Anti-pancreatic cancer antibodies
HK1214177A1 (en) Cancer peptide therapeutics
EP2511371A4 (en) Anticancer anti-mortalin peptide antibodies
GB0710212D0 (en) Processes for making and using immune complexes and components thereof
HUE048721T2 (en) Antibodies against human cd38
TN2011000153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide